首頁 > 市場調查報告書 > 製藥

神經疾病

癡呆症藥物市場:按藥物類別、分銷渠道、地區 - 規模、份額、前景、機會分析，2022-2030

市場調查報告書

商品編碼

1110217

癡呆症藥物市場:按藥物類別、分銷渠道、地區 - 規模、份額、前景、機會分析，2022-2030

Dementia Drugs Market, by Drug Class, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年07月22日 | 出版商:

Coherent Market Insights | 英文 173 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

癡呆症是一種影響大腦功能並降低記憶力和思維能力的疾病。阿爾茨海默病是 65 歲以上人群中最常見和最大的癡呆形式（>60%）。癡呆症是由多種主要或次要影響大腦的疾病和損傷引起的，例如阿爾茨海默病和中風。它影響記憶、思維、定向、理解、算術、學習能力、語言和判斷力。認知功能受損通常伴隨著情緒、情緒控制、行為或動機的變化，但有時也伴隨著這些變化。癡呆症的主要原因是由於基因突變導致神經細胞中一種稱為BETA-澱粉樣蛋白的蛋白質的積累。癡呆症是一種無法治癒的疾病，但在所有情況下都會給予對症治療。正在開發以 BETA-澱粉樣蛋白在癡呆中的作用為中心的治療方法。

市場動態

監管機構不斷增加的產品批准是癡呆症治療市場增長的主要驅動力。例如，2021 年 6 月 24 日，製藥公司禮來公司（Eli Lilly & Co.）宣布禮來公司（Lilly & Co.）針對阿爾茨海默病（AD）的研究性抗體治療藥物多那奈（donanemab）被美國食品藥品監督管理局（Food and Drug Administration）（ FDA ）批准為突破性療法宣布已被任命。突破性療法認定表明，與 FDA 批准的療法相比，用於治療嚴重疾病的藥物可能在臨床重要終點方面表現出顯著改善。它旨在在有初步臨床證據時加快開發和審查。阿爾茨海默病是最常見的癡呆症，佔病例的 60-80%。

本研究的主要特點

本報告對全球癡呆治療市場進行了深入分析，提供了以 2021 年為基準年的預測期（2022-2030 年）的市場規模和復合年增長率 (CAGR%)。
解釋不同細分市場的潛在收入機會，並描述該市場具有吸引力的投資建議矩陣。
該研究還提供了有關市場驅動因素、抑制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭策略的重要見解。
基於公司亮點、產品組合、關鍵亮點、財務業績和戰略等參數的全球癡呆治療市場主要參與者的概況。
本次調查涵蓋的主要公司包括衛材、楊森製藥、百健製藥、Forest Laboratories, Inc.、禮來公司、諾華製藥、賽諾菲、阿斯利康、F Hoffmann-La羅氏、默克公司、Valeant Pharmaceutical International、輝瑞公司和梯瓦製藥工業有限公司。
本報告中的見解將使營銷人員和公司高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
全球癡呆症治療市場報告迎合了該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和財務分析師。
它將通過用於分析全球癡呆症藥物市場的各種戰略矩陣促進決策制定。

內容

第 1 章目的和先決條件

調查目的
先決條件
縮寫說明

第二章市場展望

舉報內容
- 市場定義和範圍
執行摘要
- 市場快照:按藥物類別
- 市場快照:按分銷渠道
- 市場概況:按地區劃分
連貫的機會圖 (COM)

第 3 章市場動態、法規和趨勢分析

市場動態
- 驅動程序
- 約束因素
- 市場機會
主要亮點
市場趨勢
PEST 分析
政府和非政府舉措
流行病學

第 4 章全球癡呆症藥物市場 - 冠狀病毒 (COVID-19) 大流行的影響

整體影響
政府舉措
COVID-19 對市場的影響

第 5 章全球癡呆藥物市場，按藥物類別，2017-2030 年

MAO抑製劑
膽鹼酯□抑製劑
谷氨酸抑製劑

第 6 章全球癡呆症藥物市場:按分銷渠道，2017-2030 年

醫院藥房
零售藥房
其他

第 7 章。全球癡呆藥物市場:按地區劃分，2017-2030 年

北美
美國
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲地區
歐洲
英國
德國
意大利
法國
西班牙
俄羅斯
其他歐洲
亞太地區
中國
印度
日本
東盟
澳大利亞
韓國
其他亞太地區
中東
海合會
以色列
其他中東
非洲
北非
中非
南非

第 8 章競爭格局

熱圖分析
市場份額分析
公司簡介
- Eisai, Inc.
- Janssen Pharmaceuticals, Inc.
- Biogen Pharmaceuticals
- Forest Laboratories, Inc.
- Eli Lilly and Company
- Novartis AG
- Sanofi S.A.
- AstraZeneca GmbH
- F. Hoffmann-La Roche
- Merck & Co., Inc.
- Pfizer Inc.
- Teva Pharmaceuticals Industries Ltd.

第九章章節

調查方法介紹
關於出版商

簡介目錄

Product Code: CMI1664

Dementia is a form of disease that affects the functioning of the brain resulting in decline in memory or other thinking skills. Alzheimer's disease is the most common and largest form of dementia (in over 60% cases), which is observed among people aged 65 years and above. Dementia results from a variety of diseases and injuries that primarily or secondarily affect the brain, such as Alzheimer's disease or stroke. It affects memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgment. The impairment in cognitive function is commonly accompanied, and occasionally preceded, by changes in mood, emotional control, behavior, or motivation. Accumulation of a protein called beta amyloid in the spaces between nerve cells due to genetic mutation is a major cause of dementia. Although dementia is not treatable, symptomatic treatment is followed in all cases. Research is being carried out to develop therapies centered on the role of beta-amyloid in dementia.

Market Dynamics

Increasing product approval by regulatory authorities is the major driving factor for growth of the dementia drugs market. For instance, on June 24, 2021, Eli Lilly and Company, a pharmaceutical company announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company's investigational antibody therapy for Alzheimer's disease (AD). The Breakthrough Therapy designation aims to expedite development and review of drugs that are intended to treat a serious condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over already available therapies that have received full FDA approval. Dementia due to Alzheimer's disease is the most common form of dementia, accounting for 60 to 80 percent of all cases.

Key features of the study:

This report provides an in-depth analysis of the global dementia drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global dementia drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Eisai, Inc., Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca GmbH, F. Hoffmann-La Roche, Merck & Co., Inc., Valeant Pharmaceutical International, Pfizer Inc., and Teva Pharmaceuticals Industries Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global dementia drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dementia drugs market

Detailed Segmentation:

Global Dementia Drugs Market, By Drug Class:
- MAO Inhibitors
- Cholinesterase Inhibitors
- Glutamate Inhibitor
Global Dementia Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
Global Dementia Drugs Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Region/Country
- South Africa
- Central Africa
- North Africa
Company Profiles
- Eisai, Inc. *
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Janssen Pharmaceuticals, Inc.
- Biogen Pharmaceuticals
- Forest Laboratories, Inc.
- Eli Lilly and Company
- Novartis AG
- Sanofi S.A.
- AstraZeneca GmbH
- Hoffmann-La Roche
- Merck & Co., Inc.
- Valeant Pharmaceutical International
- Pfizer Inc.
- Teva Pharmaceuticals Industries Ltd.

"" marked represents similar segmentation in other categories in the respective section.*

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Key Highlights
Market Trends
PEST Analysis
Government & Non-Government Initiatives
Epidemiology

4. Global Dementia Drugs Market- Impact of Coronavirus (Covid-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the market

5. Global Dementia Drugs Market, By Drug Class, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
MAO Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Cholinesterase Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Glutamate Inhibitor
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Dementia Drugs Market, By Distribution Channel, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 20230
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)

7. Global Dementia Drugs Market, By Region, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
North Africa
Central Africa
South Africa